Printer Friendly

Syndax unveils promising study data for entinostat in Hodgkin's lymphoma.

M2 PHARMA-December 12, 2011-Syndax unveils promising study data for entinostat in Hodgkin's lymphoma(C)2011 M2 COMMUNICATIONS

12 December 2011 - US-based Syndax Pharmaceuticals Inc said on Sunday that data from its ENGAGE 501 Phase II trial showed that entinostat, a new, oral small molecule inhibitor of class I histone deacetylases, was active as a single agent in patients with relapsed or refractory Hodgkin's lymphoma (HL).

Data showed an antitumour activity in HL patients progressing after stem cell transplantation (SCT) with bulky disease in about a third of patients within two cycles of therapy. Progression-free survival (PFS) also showed durable responses in bulky disease patients. Additionally, entinostat was well tolerated and its safety profile was consistent with previous studies allowing for future combination treatments.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 12, 2011
Previous Article:BioTheranostics unveils positive study results for Breast Cancer Index.
Next Article:USPTO reaffirms validity of four Silence Therapeutics patents.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters